Stock Details
AZN is AstraZeneca PLC's stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 65.02$. Average daily volumn in 3 months 6.92M. Market cap 207.32B



Stock symbol : AZN. Exchange : NasdaqGS. Currency : USD
Lastest price : 66.90$. Total volume : 5.64M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

AstraZeneca PLC (AZN)
Last Price
66.90$
Change
2.45
Volume
5.64M

Previous Close64.45
Open66.46
Day Range65.75-66.93
Bid66.54 x 3.1k
Ask66.93 x 4k
Volume5.64M
Average Volume6.92M
Market Cap207.32B
Beta0.12
52 Week Range53.63-71.70
Trailing P/EN/A
Foward P/E17.51
Dividend (Yield %)2.28%
Ex-Dividend Date2022-02-24



Financial Details


According to AstraZeneca PLC's financial reports the company's revenue in 2021 were 37.42B an increase( +42.31%) over the years 2020 revenue that were of 26.62B. In 2021 the company's total earnings were 112M while total earnings in 2020 were 3.2B(-96.27%).


Loading ...



Organization

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolis... m diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Market Cap:
207.32B
Revenue:
37.42B
Total Assets:
105.36B
Total Cash:
6.33B



News about "AstraZeneca PLC"

astrazeneca-plc-lonazn-receives-consensus-rating-of-buy-from-analysts-image

AstraZeneca PLC (LON:AZN) Receives Consensus Rating of โ€œBuyโ€ from Analysts

Source from : Defense World - 12 hours ago

AstraZeneca PLC (LON:AZN โ€“ Get Rating) has received an average recommendation of โ€œBuyโ€ from the fourteen ratings firms that are covering the company, MarketBeat Ratings reports. Six analysts have ...See details»


diversified-trust-co-increases-stake-in-astrazeneca-plc-nasdaqazn-image

Diversified Trust Co Increases Stake in AstraZeneca PLC (NASDAQ:AZN)

Source from : Defense World - 10 hours ago

Diversified Trust Co increased its position in AstraZeneca PLC (NASDAQ:AZN โ€“ Get Rating) by 14.0% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 4, ...See details»


caprock-group-inc-has-640000-position-in-astrazeneca-plc-nasdaqazn-image

CAPROCK Group Inc. Has $640,000 Position in AstraZeneca PLC (NASDAQ:AZN)

Source from : ETF Daily News - 1 days ago

CAPROCK Group Inc. increased its stake in shares of AstraZeneca PLC (NASDAQ:AZN โ€“ Get Rating) by 45.5% during the first quarter, HoldingsChannel reports. The institutional investor owned 9,643 shares ...See details»


top-analyst-reports-for-unitedhealth-chevron-astrazeneca-image

Top Analyst Reports for UnitedHealth, Chevron & AstraZeneca

Source from : YAHOO!Finance - 23 hours ago

Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Chevron Corporation (CVX), and AstraZeneca PLC (AZN).See details»


AstraZeneca: Phase III Data Show Significant Copper Mobilization From Tissues With ALXN1840

Source from : Nasdaq - 2 days ago

AstraZeneca PLC (AZN.L, AZN) said the detailed results from the positive FoCus phase III trial in Wilson disease showed that ALXN1840 met primary endpoint showing three-times greater copper ...See details»


astrazenecas-alxn1840-shows-promising-action-against-copper-metabolism-disorder-image

AstraZeneca's ALXN1840 Shows Promising Action Against Copper Metabolism Disorder

Source from : YAHOO!Finance - 2 days ago

AstraZeneca Plc (NASDAQ: AZN) announced detailed results from the positive FoCus Phase 3 trial of ALXN1840 in Wilson's disease, an inherited condition in which the body's pathway for removing excess ...See details»


short-volatility-alert-astrazeneca-plc-image

Short Volatility Alert: AstraZeneca PLC

Source from : Benzinga.com on MSN.com - 3 days ago

On Tuesday, shares of AstraZeneca PLC (NASDAQ: AZN) experienced volatile short activity. After the activity, the stock price went up 2.85% to $62.83. The overall ...See details»


astrazeneca-plc-nasdaqazn-receives-consensus-recommendation-of-buy-from-analysts-image

AstraZeneca PLC (NASDAQ:AZN) Receives Consensus Recommendation of โ€œBuyโ€ from Analysts

Source from : ETF Daily News - 9 days ago

AstraZeneca PLC (NASDAQ:AZN โ€“ Get Rating) has been given a consensus recommendation of โ€œBuyโ€ by the fifteen analysts that are currently covering the company, Marketbeat.com reports. Four equities ...See details»


Biocartis In Deal With AstraZeneca To Develop Companion Diagnostic Test For Tagrisso

Source from : Nasdaq - 3 days ago

Biocartis Group NV, a Belgium-based molecular diagnostics company, announced Wednesday that it has entered into an agreement with British drug major AstraZeneca Plc. (AZN, AZN.L) for the development ...See details»


ADRs End Lower; ArcelorMittal, AstraZeneca Trade Actively

Source from : MarketWatch - 2 days ago

By Denny Jacob International stocks trading in New York closed lower on Wednesday. The S&P/BNY Mellon index of American depositary receipts slipped 1.1% ...See details»


AstraZeneca PLC (NASDAQ: AZN) Jumps 1.70% In Recent Session, What Things You Absolutely Need To Know?

Source from : stocksregister - 10 days ago

AstraZeneca PLC (NASDAQ:AZN) price is hovering higher on Wednesday, June 15, jumping 1.70% above its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << A look at t ...See details»


astrazenecas-lynparza-gets-ema-panel-nod-for-expanded-use-in-breast-cancer-subtype-image

AstraZeneca's Lynparza gets EMA panel nod for expanded use in breast cancer subtype

Source from : Seeking Alpha - 1 days ago

A panel of the European Medicines Agency ((EMA)) recommended the expanded approvalย ofย AstraZeneca's blockbuster cancer drugย Lynparza.The EMA's Committee for Medicinal Products for ...See details»


baron-funds-expects-continued-share-appreciation-as-astrazeneca-azns-financials-compound-image

Baron Funds Expects Continued Share Appreciation as AstraZeneca (AZN)โ€™s Financials Compound

Source from : Insider Monkey - 11 days ago

Baron Funds, an asset management firm, published its โ€œBaron Health Care Fundโ€ first quarter 2022 investor letter โ€“ a copy of which can be downloaded here.See details»


AstraZeneca PLC (LON:AZN) insider upped their holding by 6.4% earlier this year

Source from : Yahoo - 19 days ago

Insiders were net buyers of AstraZeneca PLC's (LON:AZN ) stock during the past year. That is, insiders bought more stock than they sold. While we would never suggest that investors should base ...See details»